NCT01215578

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: Assistance Publique - Hôpitaux de Paris

Condition: Neuroendocrine Tumors, Pancreatic Neoplasms, Advanced Disease, Sunitinib

Signal summary

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

lack of recruitement